NSCLC Clinical Trials 2023

Browse 16 Nsclc Medical Studies Across 198 Cities
4 Phase 3 Trial · 381 Nsclc Clinics

Display Results

AllMost EffectiveMost SafeSenior FriendlyPediatricNo Placebo

Clinical Trials NSCLC Clinical Trials 2023

Reviewed by Michael Gill, B. Sc.

Image of Memorial Sloan Kettering at Basking Ridge (All Protocol Activities) in Basking Ridge, United States.

L-SABR Armfor Non-Small Cell Lung Cancer

Basking Ridge, NJ

This trial tests if adding radiation to drug therapy for NSCLC can improve treatment effectiveness.

Memorial Sloan Kettering at Basking Ridge (All Protocol Activities) (+6 Sites)Paul Romesser, MD

Image of Research Site in Chandler, United States.

Group A: Ceralasertib Plus Durvalumab Combination Therapyfor Non-Small Cell Lung Cancer

This trialwill test a new drug combo to treat advanced lung cancer after other treatments have failed.

Research Site (+11 Sites)AstraZeneca

Image of Yale New Haven Hospital in New Haven, United States.

LYL797for Breast Cancer

This trial will study a new cancer treatment, called LYL797, in patients who have triple negative breast cancer or non-small cell lung cancer that has come back or does not respond to other treatments. The first part of the trial will test different doses of LYL797 to find a safe dose. The second part of the trial will give that dose to additional patients to see if it is effective.

Yale New Haven Hospital (+18 Sites)Heidi Gillenwater, MDLyell Immunopharma, Inc.

Image of City of Hope Investigational Drug Services (IDS) in Duarte, United States.

Sasanlimabfor Non-Small Cell Lung Cancer

This trial is testing a combination of therapies, one of which is a PD-1 antagonist monoclonal antibody. The first part of the trial (Phase 1b) is testing the safety of the combination, and the second part (Phase 2) will test how well the combination works against cancer.

Waitlist Available

FDA Approved Drug

City of Hope Investigational Drug Services (IDS) (+88 Sites)Pfizer CT.gov Call CenterPfizer

Image of Centre Hospitalier de l'Université de Montréal in Montréal, Canada.

Standard Of Carefor Lung Cancer

Montréal, Canada

This trial is testing whether a new cancer treatment is better than the current standard of care.

Centre Hospitalier de l'Université de MontréalHouda Bahig, MD PhD

Image of Pacific Cancer Medical Center Inc in Anaheim, United States.

AMG 510for Non-Small Cell Lung Cancer

This trial is testing a new drug, AMG 510, to see if it works better than the current standard of care drug, docetaxel, in treating NSCLC patients with a specific KRAS mutation.

Waitlist Available

FDA Approved Drug

Pacific Cancer Medical Center Inc (+59 Sites)MDAmgen

Image of Yuma Regional Medical Center Cancer Center in Yuma, United States.

Encorafenibfor Non-Small Cell Lung Cancer

This trial is testing a new combination therapy for patients with a specific type of lung cancer. The trial will test how well the new therapy works and if it is safe.

Waitlist Available

FDA Approved Drug

Yuma Regional Medical Center Cancer Center (+99 Sites)Pfizer CT.gov Call CenterPfizer

Image of Pacific Shores Medical Group in Long Beach, United States.

Pembrolizumabfor Non-Small Cell Lung Cancer

This trial is testing a new cancer treatment that combines two drugs, one that helps the chemotherapy work better and one that fights the cancer cells directly. The goal is to see if this new treatment is more effective and has fewer side effects than current treatments.

Waitlist Available

FDA Approved Drug

Pacific Shores Medical Group (+6 Sites)Novartis PharmaceuticalsNovartis Pharmaceuticals

Image of Edward Hines Jr, VA Hospital in Hines, United States.

Group 2: Peripherally Located Chest Wall Adjacent Tumorsfor Non-Small Cell Lung Cancer

This trial will test the hypothesis that SBRT results in a higher rate of tumor control and longer overall survival compared to EBRT in medically inoperable early-stage NSCLC patients.

Waitlist Available

Edward Hines Jr, VA Hospital (+1 Sites)Matthew Harkenrider, MD

Image of Research Site in Chandler, United States.

MEDI4736 (durvalumab)for Non-Small Cell Lung Cancer

This trial is testing a new drug, MEDI4736, to see if it is better than the current standard of care for treating non-small cell lung cancer.

Waitlist Available

FDA Approved Drug

Research Site (+33 Sites)Paul Stockman, MBChB, PhDAstraZeneca

10 Nsclc Clinical Trials Near Me

Top Hospitals for Nsclc Clinical Trials

Image of Research Site in Arizona.

Research Site

Chandler

2Active Trials

0All Time Trials for Nsclc

2015First Nsclc Trial

Image of Research Site in Georgia.

Research Site

Atlanta

2Active Trials

0All Time Trials for Nsclc

2015First Nsclc Trial

Image of Research Site in Ohio.

Research Site

Canton

2Active Trials

0All Time Trials for Nsclc

2014First Nsclc Trial

Image of Memorial Sloan Kettering Cancer Center in New York.

Memorial Sloan Kettering Cancer Center

New York

2Active Trials

0All Time Trials for Nsclc

2019First Nsclc Trial

Image of Comprehensive Cancer Centers of Nevada in Nevada.

Comprehensive Cancer Centers of Nevada

Las Vegas

2Active Trials

0All Time Trials for Nsclc

2020First Nsclc Trial

Top Cities for Nsclc Clinical Trials

Image of Boston in Massachusetts.

Boston

14Active Trials

Massachusetts General HospitalTop Active Site

Image of New York in New York.

New York

11Active Trials

Memorial Sloan Kettering Cancer CenterTop Active Site

Nsclc Clinical Trials by Phase of Trial

Phase 1 Nsclc Clinical Trials

3Active Nsclc Clinical Trials

3Number of Unique Treatments

20Number of Active Locations

LYL797 Papaverine Hydrochloride ACY-241

Nsclc Clinical Trials by Age Group

18+ Nsclc Clinical Trials

16Active Nsclc Clinical Trials

L-SABR Arm Group A: Ceralasertib plus durvalumab combination therapy LYL797 Sasanlimab Standard of care AMG 510 encorafenib pembrolizumab Group 2: Peripherally Located Chest Wall Adjacent Tumors MEDI4736 (durvalumab)Treatment Pembrolizumab/Vibostolimab coformuation Papaverine Hydrochloride Nivolumab ACY-241 MEDI4736

Most Recent Nsclc Clinical Trials

Clinical Trial

Began Recruiting Date

Phase

L-SABR Arm for Non-Small Cell Lung Cancer

12/9/2022

Phase 2

Group A: Ceralasertib plus durvalumab combination therapy for Non-Small Cell Lung Cancer

9/15/2022

Phase 3

LYL797 for Breast Cancer

3/29/2022

Phase 1

Pembrolizumab/Vibostolimab coformuation for Non-Small Cell Lung Cancer

4/20/2021

Phase 2

Treatment for Non-Small Cell Lung Cancer

4/15/2021

Phase 2

Top Treatments for Nsclc Clinical Trials

Treatment Name

Active Nsclc Clinical Trials

All Time Trials for Nsclc

First Recorded Nsclc Trial

L-SABR Arm

1

1

2022

Group A: Ceralasertib plus durvalumab combination therapy

1

1

2022

LYL797

1

1

2022

Sasanlimab

1

1

2020

Standard of care

1

1

2021

About The Author

Michael Gill - B. Sc.

First Published: October 5th, 2021

Last Reviewed: September 3rd, 2023

References¹ Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29. doi: 10.3322/caac.21208. Epub 2014 Jan 7. Erratum in: CA Cancer J Clin. 2014 Sep-Oct;64(5):364. https://pubmed.ncbi.nlm.nih.gov/24399786² Timmerman RD. An overview of hypofractionation and introduction to this issue of seminars in radiation oncology. Semin Radiat Oncol. 2008 Oct;18(4):215-22. doi: 10.1016/j.semradonc.2008.04.001. https://pubmed.ncbi.nlm.nih.gov/18725106³ Gould MK, Donington J, Lynch WR, Mazzone PJ, Midthun DE, Naidich DP, Wiener RS. Evaluation of individuals with pulmonary nodules: when is it lung cancer? Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013 May;143(5 Suppl):e93S-e120S. doi: 10.1378/chest.12-2351. Review. https://pubmed.ncbi.nlm.nih.gov/23649456⁴ Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, Fakiris A, Bezjak A, Videtic G, Johnstone D, Fowler J, Gore E, Choy H. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010 Mar 17;303(11):1070-6. doi: 10.1001/jama.2010.261. https://pubmed.ncbi.nlm.nih.gov/20233825⁵ Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29. doi: 10.3322/caac.21208. Epub 2014 Jan 7. Erratum In: CA Cancer J Clin. 2014 Sep-Oct;64(5):364. https://pubmed.ncbi.nlm.nih.gov/24399786⁶ Zhang Q, Luo J, Wu S, Si H, Gao C, Xu W, Abdullah SE, Higgs BW, Dennis PA, van der Heijden MS, Segal NH, Chaft JE, Hembrough T, Barrett JC, Hellmann MD. Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade. Cancer Discov. 2020 Dec;10(12):1842-1853. doi: 10.1158/2159-8290.CD-20-0047. Epub 2020 Aug 14. https://pubmed.ncbi.nlm.nih.gov/32816849⁷ Martin ML, Correll J, Walding A, Ryden A. How patients being treated for non-small cell lung cancer value treatment benefit despite side effects. Qual Life Res. 2022 Jan;31(1):135-146. doi: 10.1007/s11136-021-02882-6. Epub 2021 May 31. https://pubmed.ncbi.nlm.nih.gov/34056687⁸ Timmerman RD. An overview of hypofractionation and introduction to this issue of seminars in radiation oncology. Semin Radiat Oncol. 2008 Oct;18(4):215-22. doi: 10.1016/j.semradonc.2008.04.001. No abstract available. https://pubmed.ncbi.nlm.nih.gov/18725106⁹ Martin ML, Correll J, Walding A, Rydén A. How patients being treated for non-small cell lung cancer value treatment benefit despite side effects. Qual Life Res. 2022 Jan;31(1):135-146. doi: 10.1007/s11136-021-02882-6. Epub 2021 May 31. https://pubmed.ncbi.nlm.nih.gov/34056687¹⁰ Timmerman RD. An overview of hypofractionation and introduction to this issue of seminars in radiation oncology. Semin Radiat Oncol. 2008 Oct;18(4):215-22. doi: 10.1016/j.semradonc.2008.04.001. https://pubmed.ncbi.nlm.nih.gov/18725106

Unbiased ResultsWe believe in providing patients with all the options.

Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.

Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.

Back to top

Terms of Service Privacy Policy Security